Top Stories
In March, Pfizer had terminated a Phase I trial of PF-08046031, an antibody-drug conjugate (ADC), in patients with melanoma and other solid tumours.
Eli Lilly returns to fund the biotech's obesity programme, with Phase I testing slated to begin by the end of the year.
A relative latecomer to the BCMA bispecific class, etentamig also demonstrated a 74% response rate versus 45.7% for investigator's choice of available therapies.
The deal for the twice-monthly subcutaneous therapy is potentially worth up to €726 million ($844 million), including an upfront payment of €62 million ($72 million).
Positive progression-free survival results from the HARMONi-2 trial were first disclosed in 2024, but now the PD-1/VEGF bispecific antibody has also improved overall survival in the study.
Conference News
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with...
ESC gets to the heart of key drug battles in cardiologyThe European Society of Cardiology (ESC) annual meeting provided lots of answers, and arguably, even more questions. The failed CARDIO-TTRansform...
- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies -- All development...
—New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacterial (NTM) Lung Disease——New Resear...
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sc...
